Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.00 -0.37 (-0.30%)
Streaming Delayed Price Updated: 12:29 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
The Reserve Bank Of South Africa Kept The Rate At 8.25%
The Reserve Bank of South Africa unanimously decided to keep the key repo rate at 8.25%, marking the fifth consecutive meeting at 2009 levels, as expected. 
Via Talk Markets
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma, underscoring a commitment to advancing innovative therapies. 
Via Benzinga
Exposures Product Safety
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients. 
Via Benzinga
Topics Stocks
Exposures US Equities
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Smart Money Is Betting Big In MRK Options
Via Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Market Analysis: Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April.... 
Via Benzinga
Exposures Product Safety
US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead
Bargain hunters may flock to the market on Wednesday following three consecutive sessions of losses. 
Via Benzinga
Merck's Cardiovascular 'Renaissance' Is Here With The First Approval Of A $10 Billion Franchise
The FDA signed off on Winrevair, a treatment for pulmonary arterial hypertension. 
Via Investor's Business Daily
Exposures Product Safety
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in... 
Via Benzinga
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression. 
Via Benzinga
Bull Market and Beyond: 2 Stocks to Buy and Hold Forever
These stocks have been providing excellent returns for a long time. 
Via The Motley Fool
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Merck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate Vaccine
Merck's Phase 3 data on V116, a 21-valent pneumococcal conjugate vaccine for adults, show promising immunogenicity across diverse populations, including those at risk. 
Via Benzinga
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
Latest in weight-loss medication trends: Eli Lilly And Co's Zepbound (tirzepatide) surges past rival Novo Nordisk A/S's Wegovy (semaglutide) in new prescriptions, signaling a shift in the obesity... 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, March 16
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of March 11-15, 2024. 
Via Talk Markets
Newly Diagnosed Cervical Cancer Patients - Merck's Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival
Merck's Keytruda in combination with chemoradiotherapy achieves significant improvement in overall survival for newly diagnosed high-risk locally advanced cervical cancer patients. Keytruda is the... 
Via Benzinga
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga
7 Dow Darlings for Investors to Buy for March Market Madness
These 7 Dow stocks are better positioned than the other 23 within the index making them strong buy considerations. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors. 
Via InvestorPlace
Topics ETFs
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
Moderna and Merck are now testing their cancer vaccine in patients with another form of skin cancer. 
Via Investor's Business Daily
What's Going On With Moderna Stock On Monday?
Merck's trial with Moderna's V940 for advanced cutaneous squamous cell carcinoma. The neoadjuvant and adjuvant therapy with pembrolizumab, aiming for superior event-free survival. Phase 3 expansion... 
Via Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
These businesses can pack a punch in your portfolio over the long run. 
Via The Motley Fool
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed. 
Via Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.